{"url":"https://newsforagent.com/news/2026-10-28/junshi-biosciences-neotorch-final-results","markdown_url":"https://newsforagent.com/news/2026-10-28/junshi-biosciences-neotorch-final-results.md","title":"Shanghai Junshi Biosciences Reports Positive Final Phase 3 NEOTORCH Results","headline":"Shanghai Junshi Biosciences Reports Positive Final Phase 3 NEOTORCH Results for Toripalimab in Resectable NSCLC","description":"Shanghai Junshi Biosciences reported positive final Phase 3 NEOTORCH results for perioperative toripalimab plus chemotherapy in resectable stage II-III NSCLC.","section":"Research & Clinical Trials","published_at":"2026-10-28T04:15:16+00:00","modified_at":"2026-10-28T04:15:16+00:00","author":"News Desk","key_takeaways":["Final Phase 3 NEOTORCH results showed significant and durable improvements in event-free survival, major pathological response and overall survival for perioperative toripalimab plus chemotherapy in resectable stage II-III non-small cell lung cancer.","The data included a median follow-up of 48.2 months with no new safety signals.","China's sNDA for the stage II-III label expansion was accepted in July 2026, following the December 2023 NMPA approval."],"companies":[{"name":"Shanghai Junshi Biosciences","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0009v3u/shanghai-junshi-biosciences","website":"http://junshipharma.com"}],"source":{"publisher":"TradingView","title":"Shanghai Junshi Biosciences Reports Positive Final Phase 3 NEOTORCH Results","url":"https://www.tradingview.com/news/tradingview:8cba9b4c175cd:0-shanghai-junshi-biosciences-reports-final-phase-3-neotorch-results/"},"other_sources":[],"tags":["Research & Clinical Trials","Shanghai Junshi Biosciences"],"body_markdown":"Shanghai Junshi Biosciences reported positive final Phase 3 NEOTORCH results for perioperative toripalimab plus chemotherapy in resectable stage II-III non-small cell lung cancer, showing significant and durable improvements in event-free survival, major pathological response and overall survival. [TradingView](https://www.tradingview.com/news/tradingview:8cba9b4c175cd:0-shanghai-junshi-biosciences-reports-final-phase-3-neotorch-results/) published the announcement on October 28, 2026.\n\n## What the NEOTORCH Final Analysis Showed\n\nThe final analysis covered patients with resectable stage II-III non-small cell lung cancer treated with perioperative toripalimab plus chemotherapy. The company said the regimen demonstrated significant and durable improvements in event-free survival and overall survival, alongside major pathological response. The data included a median follow-up of 48.2 months, and the company said there were no new safety signals. [Shanghai Junshi Biosciences](https://akta.pro/company-profiles/0009v3u/shanghai-junshi-biosciences) is a Shanghai-headquartered, dual-listed biopharmaceutical company founded in 2012 that develops antibodies for oncology, autoimmune, metabolic and infectious disease patients across China and more than 40 countries.\n\n## Regulatory Path for the Stage II-III Label\n\nChina's supplemental new drug application for toripalimab in this setting was accepted in July 2026, according to the announcement. The application seeks to expand the indication from stage IIIA-IIIB to stage II-III. The National Medical Products Administration approved toripalimab for the earlier stage IIIA-IIIB indication in December 2023.\n\n## Toripalimab's Earlier Approvals and Partnerships\n\nAccording to akta.pro [company records](https://akta.pro/company-data), the NEOTORCH Phase III final analysis in May 2026 met the event-free survival and major pathological response endpoints with a 60% risk reduction in stage II-III resectable non-small cell lung cancer perioperative treatment. The same records show that the NMPA approved toripalimab with RemeGen's disitamab vedotin in May 2026 for first-line HER2-expressing urothelial carcinoma, the 13th Chinese Mainland indication and the first approved domestic immuno-ADC combination. Full-year 2025 total revenue was RMB 2,498 million, a roughly 28% increase year on year, driven primarily by toripalimab domestic sales of RMB 2,068 million, up 38% year on year.\n\n## Junshi's First-Half Results and Earlier Financing\n\nIn September 2026, The future of trading reported that Junshi's FY26 first-half revenue was RMB 1.7 billion, up 45%, with a profit of RMB 25.5 million. Research and development expenses fell 14% to RMB 643.94 million, while selling and distribution costs rose 4% to RMB 507.17 million. In June 2025 the company raised RMB 940 million through a placing of new H shares, according to akta.pro company records.\n\n## What Comes Next for the Stage II-III Filing\n\nThe supplemental new drug application accepted in July 2026 covers the stage II-III expansion, following the December 2023 approval for stage IIIA-IIIB. The company's own [announcement](http://junshipharma.com) describes the NEOTORCH data.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}